Padagis Israel Pharmaceuticals Ltd. et al. vs Bausch Health Ireland Limited et al.

Notice: refund approved

Petitioner's Request for Refund of Post-Institution Fees

Institution Decision: Deny

Patent Owner's Second Revised Mandatory Notices

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5

Patent Owner's Corrected Preliminary Response

Petitioners' Reply to Patent Owner's Corrected Preliminary Response

Ex. 3001

Decision Granting Patent Owner’s Unopposed Motions for Pro Hac Vice Admission of Thomas P. Steindler and Christopher M. Bruno

Patent Owner's Motion for Admission Pro Hac Vice of Thomas P. Steindler

Patent Owner's Motion for Admission Pro Hac Vice of Christopher M. Bruno

Declaration of Thomas P. Steindler in Support of Patent Owner's Motion for Admission Pro Hac Vice

Declaration of Christopher M. Bruno in Support of Patent Owner's Motion for Admission Pro Hac Vice

Patent Owner's Updated Exhibit List

Patent Owner's Preliminary Response

Opinion, No. 20-5426

U.S. Pat. No. 11,679,116

Notice of Abandonment of U.S. Patent Application No. 16/179,576

Plaintiffs’ Proposed Findings of Fact and Conclusions of Law, No. 20-5426

Padagis Opening Post Trial Brief, No. 20-5426

Padagis Proposed Findings of Fact and Conclusions of Law, No. 20-5426

Complaint, No. 22-4248

Stipulation, No. 22-4248

Waiver of the Service of Summons, No. 22-4248

Complaint, No. 23-3393

Order Consolidating Cases, No. 22-4248

Padagis Invalidity Contentions, No. 22-4248

Stipulation and Order on Pretrial Schedule and Discovery, No. 22-4248

Letter from William P. Deni, Jr. to Hon. Madeline Cox Arleo, U.S.D.J., No 22-4248

Joint Proposed Discovery Plan, No. 22-4248

Padagis Amended Invalidity Contentions, No. 22-4248

Memorandum from Katherine K. Vidal, Under Sec’y of Com. for Intell. Prop. & Dir. of the USPTO to Members of the Pat. Trial & Appeal Bd.

U.S. Patent Assignment Reel 059759, Frame 0311-15

First Amended Complaint, No. 22-4248

Opening Statement on Behalf of the Padagis Defendants, No. 20-5426

Trial Transcript, No. 20-5426

Padagis Answer to Complaint, Affirmative Defenses and Counterclaims, No. 22-4248

Patent Owner's Revised Mandatory Notices

Patent Owner's Revised Power of Attorney

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

Notice : Mandatory Notice

Notice : Power of Attorney

Petition for Inter Partes Review of U.S. Patent No. 11,311,482

Petitioners' Power of Attorney

U.S. Patent No. 11,311,482

Prosecution History of the ’482 patent

Curriculum Vitae of Dr. Robert Schwartz

Declaration of Dr. Narasimha Murthy

Curriculum Vitae of Dr. Narasimha Murthy

International Patent Publication WO 2016/205001

Topical Tazarotene in Acne Vulgaris: Treatment Approaches, CUTIS

Kircik, L., Tretinoin Microsphere Gel Pump 0.04% Versus Tazarotene Cream

Chim, C., Acne Vulgaris, ACSAP 2016 Book 2

Shalita, Tazarotene Gel is Safe and Effective in the Treatment of Acne

U.S. Patent Pub. No. US 2012/0129824

Prescribing Information for Tazorac® Cream

ClinicalTrials.gov, “A Phase 2 Dosing Ranging, Evaluator-Blinded Study"

IQVIA Sales Data For 0.05% Tazarotene For The Indication Of Acne Vulgaris

Declaration of James Booydegraaf

Prescribing Information for FABIOR® Foam

Eichenfield, Evidence-Based Recommendations for the Treatment of Acne

Zaenglein et al., Guidelines of care for the management of acne vulgaris

Gregoriou et al., Use of tazarotene foam for the treatment of acne vulgaris

Kober, M-M. et al., Acneiform Eruptions in Dermatology

Dosik, Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel

Patel, Novel microemulsion-based gel formulation of tazarotene for acne

U.S. Pat. Appl. Pub. No. US 2012/0328670

Kircik, L., Importance of Vehicles in Acne Therapy

Bausch Health Companies, Inc. Duobrii® Citizen Petition

Arazlo Webpage

Arazlo Vehicle Webpage

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 1

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 2

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 3

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 4

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 5

’482 patent and ’576 application claim comparison chart

Singh, Dosage Forms: Non-Parenteral in Encyclopedia of Pharmaceutical Tech

U.S. Patent Pub. No. 2012/0328670

Bausch v. Padagis, Case No. 2:20-cv-05426, Testimony of Dr. PIllai

Prescribing Information for DIFFERIN® Lotion

Tegeli, Pemulen as a Versatile Emulsifier

Federal Court Management Statistics, U.S. District Courts

NDA 20600 Tazorac 0.05% and 0.01% Medical Review Part 3

National Medical and Treatment Audit Diagnosis Allocation Fact Sheet

Eastman, Assessing Attributes of Topical Vehicles for the Treatment of Acne

Russell, J., Topical Therapy for Acne

Draelos, Therapeutic Moisturizers, Dermatologic Aspects of Cosmetics 2000

Rawlings, et al., A review on the extensive skin benefits of mineral oil

Lubrizol, Pharmaceutical Bulletin No. 8

Ismail, Subchronic and Chronic Toxicity of Tazarotene Gel

Gennaro, A. (1990). Remington’s Pharmaceutical Sciences

Fiume et al., Int. J. Toxicol.

Prosecution History of U.S. Pat. App. No. 17/366,871

WO 2012/087443

Declaration of Dr. Robert Schwartz